First-in-human study underway for non-invasive vision correction technology
TECLens, Inc., announced that the first patient has undergone treatment with its quantitative corneal crosslinking (qCXL™) technology.
The first-in-human trial is assessing the safety and efficacy of the CXLens® system for non-invasive refractive vision correction, which, unlike traditional surgical refractive procedures that cut or remove tissue, instead creates new molecular bonds in precise locations that cause these targeted areas to reshape and improve vision, according to the company’s press release.
The non-invasive, epithelium-on treatment can be performed in-office. The system uses proprietary treatment planning technology that offers personalized planning and real-time monitoring. The study will focus particularly on patients with presbyopia.
Related Content
